BR100 Increased By (0.44%)
BR30 Increased By (1.39%)
KSE100 Increased By (0.62%)
KSE30 Increased By (0.61%)
BECO 5.43 Decreased By ▼ -0.06 (-1.09%)
BML 55.69 Decreased By ▼ -1.07 (-1.89%)
BOP 35.38 Increased By ▲ 0.26 (0.74%)
CNERGY 8.20 Increased By ▲ 0.05 (0.61%)
DCL 11.55 Increased By ▲ 0.04 (0.35%)
FCCL 58.36 Increased By ▲ 1.61 (2.84%)
FCSC 5.12 Decreased By ▼ -0.03 (-0.58%)
FFL 17.84 Decreased By ▼ -0.04 (-0.22%)
FNEL 1.25 No Change ▼ 0.00 (0%)
HUMNL 11.07 Decreased By ▼ -0.05 (-0.45%)
KEL 8.75 Increased By ▲ 0.33 (3.92%)
KOSM 6.69 Increased By ▲ 0.11 (1.67%)
MLCF 107.15 Increased By ▲ 3.85 (3.73%)
NBP 201.73 Increased By ▲ 1.55 (0.77%)
PACE 11.30 Increased By ▲ 0.01 (0.09%)
PAEL 44.49 Increased By ▲ 1.02 (2.35%)
PIAHCLA 29.41 Increased By ▲ 1.92 (6.98%)
PIBTL 18.64 Increased By ▲ 0.94 (5.31%)
PPL 247.98 Increased By ▲ 3.66 (1.5%)
PRL 35.29 Decreased By ▼ -0.14 (-0.4%)
PTC 66.14 Increased By ▲ 0.79 (1.21%)
SEARL 95.49 Increased By ▲ 2.17 (2.33%)
SSGC 32.04 Decreased By ▼ -0.90 (-2.73%)
TELE 8.87 Decreased By ▼ -0.04 (-0.45%)
THCCL 66.61 Decreased By ▼ -0.11 (-0.16%)
TPLP 10.57 Decreased By ▼ -0.26 (-2.4%)
TREET 25.30 Increased By ▲ 0.18 (0.72%)
TRG 64.40 Decreased By ▼ -0.50 (-0.77%)
WAVES 10.90 Decreased By ▼ -0.03 (-0.27%)
WTL 1.26 Increased By ▲ 0.01 (0.8%)
World

Some 3,000 to 5,000 Hungarians could participate in clinical trials of Russian vaccine

  • Kasler said a Hungarian delegation of medical experts had received "detailed notification" about the Russian vaccine in Moscow.
Published December 7, 2020 Updated December 7, 2020 04:22pm
By

BUDAPEST: Some 3,000 to 5,000 Hungarians could participate in clinical trials of Russia's Sputnik V vaccine against COVID-19, Hungarian Human Resources Minister Miklos Kasler said on his Facebook page on Monday.

Kasler said a Hungarian delegation of medical experts had received "detailed notification" about the Russian vaccine in Moscow, and observed "that the vaccine is being manufactured with the latest technology and with WHO protocols being applied."

Comments

Comments are closed for this article.